Semaglutide and Aging: Can It Extend Lifespan in Mice?

What did the semaglutide aging study find?

Published in Nature on September 2, the study began treatment when female mice were 20 months old. In the survival experiment, treatment continued until death: median lifespan was 834 days with semaglutide and 742 days in controls. These figures describe total lifespan, rather than time survived after treatment began. [Nature study](https://www.nature.com/articles/s41586-026-10940-7)

A separate cohort received treatment for three months. Researchers found better performance on tests involving memory, coordination, muscle function and endurance, alongside changes in cellular features associated with aging. Measuring both survival and function strengthens the scientific interest: a longer life is more valuable if physical and cognitive abilities are also preserved. However, these mouse tests cannot establish improvements in human independence or dementia risk. [Nature study](https://www.nature.com/articles/s41586-026-10940-7)

Were the benefits explained by eating fewer calories?

Semaglutide mimics GLP-1, a hormone involved in appetite and blood-sugar regulation. To investigate whether eating less explained the results, researchers compared treated mice with another group receiving a diet containing 24% fewer calories for five months. Both interventions protected against several declines seen in untreated animals. [NIH research report](https://www.nih.gov/news-events/nih-research-matters/glp-1-drug-slows-aging-mice)

Semaglutide produced additional improvements in exploration, spatial memory and glucose tolerance. Daytime energy expenditure also differed despite matched calorie intake. The interpretation is that the interventions may influence aging through partly different pathways. This comparison does not establish how much of the survival benefit came from appetite suppression, metabolic changes or other drug effects. [NIH research report](https://www.nih.gov/news-events/nih-research-matters/glp-1-drug-slows-aging-mice)

Should people take semaglutide to live longer?

Semaglutide already has demonstrated benefits for defined patient groups. In March 2024, the FDA approved Wegovy to reduce cardiovascular death, heart attack and stroke risk in adults with established cardiovascular disease and overweight or obesity. That decision rested on human clinical evidence. Preventing specific cardiovascular events does not, by itself, demonstrate that a medicine slows the underlying aging process. [FDA approval announcement](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or)

Potential benefits must also be weighed against adverse effects, including nausea, vomiting, diarrhea and constipation. For a proposed longevity treatment, a central question would be whether sustained use improves meaningful health outcomes enough to justify its risks in the intended population. People considering semaglutide should discuss their medical indications and treatment goals with a clinician; an animal aging result cannot supply that individual benefit-risk assessment. [FDA safety information](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or)